<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>UNITED STATES</B></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>Washington, D.C. 20549</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>FORM 8-K</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>CURRENT REPORT</B></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>Pursuant to Section 13
OR 15(d) of The Securities Exchange Act of 1934</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
April 13, 2012 (April 6, 2012)</P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>InferX Corporation</B></P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center; text-indent: 0pt">Delaware</TD>
    <TD STYLE="width: 34%; text-align: center; text-indent: 0pt">0-51720</TD>
    <TD STYLE="width: 33%; text-align: center; text-indent: 0pt">54-1614664</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0pt">(State of other jurisdiction</TD>
    <TD STYLE="text-align: center; text-indent: 0pt">(Commission</TD>
    <TD STYLE="text-align: center; text-indent: 0pt">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; text-indent: 0pt">of incorporation)</TD>
    <TD STYLE="text-align: center; text-indent: 0pt">File Number)</TD>
    <TD STYLE="text-align: center; text-indent: 0pt">Identification No.)</TD></TR>
</TABLE>
<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="text-align: center; vertical-align: top">
    <TD STYLE="text-align: center; width: 50%; padding-left: 27pt">46950 Jennings Farm Drive</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="text-align: center; vertical-align: top; padding-left: 36pt">Suite 290, Sterling, VA</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; text-indent: 0pt">20164</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="text-align: center; text-indent: 0pt">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif">Registrant&#8217;s telephone
number, including area code: (703) 444-6030</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 6, 2012, as
a result of a deadlocked Board of Directors on which B.K. Gogia, Chairman, and Vijay Suri, President and CEO of the registrant
(&quot;InferX&quot;), were the only two members on the Board, the following employees submitted to Vijay Suri a letter of resignation: B.K. Gogia, President, Technology Solutions Group, Raimondo Piluso,
COO and Vice President of Business Development, Jerzy Bala, CTO, and Rahul Argade, Senior Director. B.K. Gogia maintains his position
as Chairman of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequently, Jerzy
Bala, CTO and Rahul Argade, Senior Director rescinded their resignations based on the strategy and
direction presented by the CEO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The employees submitted
the joint letter of resignation demanding that Vijay Suri execute a term sheet from a group of three executives (Anomaly Analytics&ndash;
a shell company with no revenue or current clients) that proposed that two of them serve as members of the InferX Board along with
Messrs. Gogia and Suri and serve as a new management team--a new President and CEO and a Senior Vice President of NextGen Analytics.
Anomaly Analytics proposed that Vijay Suri serve as Executive Vice President of a new division named InferX Services and Solutions
and that B.K. Gogia serve as Executive Vice President of another new division, Health Care Programs, both reporting to the new
President and CEO. Anomaly Analytics proposed that it provide initial financing, obtain contracts that it stated it was already
in the process of negotiating with groups that it believed required InferX's predictive analytics software solution and based the
grant of additional warrants to purchase InferX shares of common stock upon an increase in InferX's market capitalization, obtaining
additional financing and obtaining contracts for the sale of InferX's predictive analytics software solution. InferX has been negotiating
with the three principals of Anomaly Analytics since December 2011.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vijay Suri refused
to execute the Anomaly Analytics term sheet based upon concerns regarding the amount of performance based warrants, uncertainty
and lack of clarity of the revenue split with Anomaly Analytics (the one principal who would not be joining the InferX executive
team and serving on InferX's Board) for business opportunities presented by Anomaly Analytics lack of specificity of the above
mentioned contract, with no firm closing dates or no concrete dollar amounts associated with the contract or the business model
as to how this contract relationship will generate revenue. This was offered by Anomaly Analytics on a &ldquo;best effort&rdquo;
basis. Mr. Suri was also uncomfortable with the dual role of the new CEO and Senior Vice President of InferX as also being the
owners of Anomaly Analytics. Vijay Suri wanted InferX to execute a term sheet from Rationalwave that proposed a financing of up
to $2 million subject to InferX installing a new CEO and eliminating significant liabilities from its balance sheet, including
having certain holders of warrants, convertible debt and Series B preferred stock convert to equity. The employees who resigned
did not oppose the terms of the Rationwave term sheet but were concerned about the amount of time the clean-up of the balance sheet
would take, InferX's immediate financial needs, the belief that InferX would benefit from the management expertise and shared vision
for InferX's pursuit of new business opportunities by the Anomaly Analytics' principals joining InferX and the timeliness of installing
new leadership which both the Anomaly Analytics and Rationalwave term sheets demanded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vijay Suri is in the
process of interviewing for persons to replace those employees who have resigned and to addressing the preconditions for an investment
in InferX by Rationalwave.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">Item 2.04&#9;Triggering Events
That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 12, 2012 Rahul
Argade, the holder of an 8% secured convertible debenture (the &ldquo;Debenture&rdquo;), issued pursuant to a Debenture and Warrant
Purchase Agreement dated December 23, 2009 among InferX and certain purchasers, notified InferX that it was in default under the
terms of the Debenture for failure to repay the principal amount of $100,000 plus interest due and that he would be exercising
his default remedies under the Debenture, including the default interest rate of 22% on the unpaid principal balance effective
as of April 7, 2012. The Debenture is secured by all assets of InferX, including its intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: center; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif"><B>SIGNATURES</B></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: left; text-indent: 0pt; margin: 0; font: 10pt Times New Roman, Times, Serif">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; text-indent: 0pt">Date: April 13, 2012</TD>
    <TD COLSPAN="2" STYLE="text-align: left; font-weight: bold; text-indent: 0pt"><FONT STYLE="font-variant: small-caps">InferX
    Corporation</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt">By:</TD>
    <TD STYLE="text-align: left; border-bottom: black 2px solid; text-indent: 0pt">/s/ Vijay Suri</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt">Vijay Suri</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: 0pt">President and CEO</TD></TR>
</TABLE>
<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v309263_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 16131}]
{"company-data": {"conformed-name": "INFERX CORP", "cik": "0001329548", "assigned-sic": "7370", "irs-number": "541614664", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51720", "film-number": "12757937"}, "business-address": {"street1": "46950 JENNINGS FARM DR.", "street2": "STE 290", "city": "STERLING,", "state": "VA", "zip": "20164-8679", "phone": "(703) 444-6030"}, "mail-address": {"street1": "46950 JENNINGS FARM DR.", "street2": "STE 290", "city": "STERLING,", "state": "VA", "zip": "20164-8679"}, "former-company": {"former-conformed-name": "BLACK NICKEL ACQUISITION CORP I", "date-changed": "20050608"}}
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 13, 2012 (April 6, 2012)
InferX Corporation
(Exact name of registrant
as specified in its charter)
Delaware
0-51720
54-1614664
(State of other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
46950 Jennings Farm Drive
Suite 290, Sterling, VA
20164
(Address of principal executive offices)
(Zip Code)
Registrant's telephone
number, including area code: (703) 444-6030
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 6, 2012, as
a result of a deadlocked Board of Directors on which B.K. Gogia, Chairman, and Vijay Suri, President and CEO of the registrant
("InferX"), were the only two members on the Board, the following employees submitted to Vijay Suri a letter of resignation: B.K. Gogia, President, Technology Solutions Group, Raimondo Piluso,
COO and Vice President of Business Development, Jerzy Bala, CTO, and Rahul Argade, Senior Director. B.K. Gogia maintains his position
as Chairman of the Board of Directors.
Subsequently, Jerzy
Bala, CTO and Rahul Argade, Senior Director rescinded their resignations based on the strategy and
direction presented by the CEO.
The employees submitted
the joint letter of resignation demanding that Vijay Suri execute a term sheet from a group of three executives (Anomaly Analytics–
a shell company with no revenue or current clients) that proposed that two of them serve as members of the InferX Board along with
Messrs. Gogia and Suri and serve as a new management team--a new President and CEO and a Senior Vice President of NextGen Analytics.
Anomaly Analytics proposed that Vijay Suri serve as Executive Vice President of a new division named InferX Services and Solutions
and that B.K. Gogia serve as Executive Vice President of another new division, Health Care Programs, both reporting to the new
President and CEO. Anomaly Analytics proposed that it provide initial financing, obtain contracts that it stated it was already
in the process of negotiating with groups that it believed required InferX's predictive analytics software solution and based the
grant of additional warrants to purchase InferX shares of common stock upon an increase in InferX's market capitalization, obtaining
additional financing and obtaining contracts for the sale of InferX's predictive analytics software solution. InferX has been negotiating
with the three principals of Anomaly Analytics since December 2011.
Vijay Suri refused
to execute the Anomaly Analytics term sheet based upon concerns regarding the amount of performance based warrants, uncertainty
and lack of clarity of the revenue split with Anomaly Analytics (the one principal who would not be joining the InferX executive
team and serving on InferX's Board) for business opportunities presented by Anomaly Analytics lack of specificity of the above
mentioned contract, with no firm closing dates or no concrete dollar amounts associated with the contract or the business model
as to how this contract relationship will generate revenue. This was offered by Anomaly Analytics on a "best effort"
basis. Mr. Suri was also uncomfortable with the dual role of the new CEO and Senior Vice President of InferX as also being the
owners of Anomaly Analytics. Vijay Suri wanted InferX to execute a term sheet from Rationalwave that proposed a financing of up
to $2 million subject to InferX installing a new CEO and eliminating significant liabilities from its balance sheet, including
having certain holders of warrants, convertible debt and Series B preferred stock convert to equity. The employees who resigned
did not oppose the terms of the Rationwave term sheet but were concerned about the amount of time the clean-up of the balance sheet
would take, InferX's immediate financial needs, the belief that InferX would benefit from the management expertise and shared vision
for InferX's pursuit of new business opportunities by the Anomaly Analytics' principals joining InferX and the timeliness of installing
new leadership which both the Anomaly Analytics and Rationalwave term sheets demanded.
-
1
-
Vijay Suri is in the
process of interviewing for persons to replace those employees who have resigned and to addressing the preconditions for an investment
in InferX by Rationalwave.
Item 2.04	Triggering Events
That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.
On April 12, 2012 Rahul
Argade, the holder of an 8% secured convertible debenture (the "Debenture"), issued pursuant to a Debenture and Warrant
Purchase Agreement dated December 23, 2009 among InferX and certain purchasers, notified InferX that it was in default under the
terms of the Debenture for failure to repay the principal amount of $100,000 plus interest due and that he would be exercising
his default remedies under the Debenture, including the default interest rate of 22% on the unpaid principal balance effective
as of April 7, 2012. The Debenture is secured by all assets of InferX, including its intellectual property.
-
2
-
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
Date: April 13, 2012
InferX
    Corporation
By:
/s/ Vijay Suri
Vijay Suri
President and CEO
-
3
-